Zheng Quan Ri Bao·2025-12-12 10:30Group 1 - The core viewpoint of the article highlights the approval of Novartis' innovative drug, Noreda® (Acrylamide Hydrochloride Tablets), as the first non-immunosuppressive therapy for IgA nephropathy in China, addressing a significant treatment gap in this area [1][3] - IgA nephropathy is prevalent among young adults in China, particularly those aged 20 to 30, with a high risk of progression to kidney failure if not effectively managed [1] - The drug is expected to be used in conjunction with existing standard treatments, providing new options for long-term disease management for patients [1][3] Group 2 - JD Health will leverage its robust pharmaceutical health service ecosystem to deepen its focus on chronic disease management, particularly in kidney diseases [1] - The collaboration with a leading global pharmaceutical company like Novartis aims to introduce cutting-edge therapeutic drugs and comprehensive digital health management solutions for patients [1][3] - JD Health's capabilities in supply chain fulfillment and professional pharmacist services will enhance the accessibility and precision of innovative drugs reaching patients nationwide [3]